PSMD1 and COVID-19: To analyze the ability of the multiplex immunoassay to correctly discriminate between positive and negative samples, SARS-CoV-2 anti-S1, anti-NC and anti-RBD IgG antibodies were assayed in the prepandemic samples (n = 40) and COVID-19 samples (n = 165).